Skip to main content

Table 1 Generalities and patient baseline of the included studies

From: Cell therapies for chondral defects of the talus: a systematic review

Author, year Journal Study Design Follow-up (months) Treatment Procedures (n) Female (%) Mean age Mean BMI Mean defect size (cm2)
Buda et al. [51] Int Orthop Retrospective 48.0 Control group (mACI) 40 37.5 31.4   1.7
BMAC 40 32.5 30.2   1.8
Desando et al. [52] Cartilage Prospective 36.0 Control group (mACI) 7 42.9 31.2   1.8
36.0 BMAC 15 33.3 31.0  
Guney et al. [53] Knee Surg Sports Traumatol Arthrosc Prospective 47.3 Control group (MFX) 19 37.4 47, 4   
40.4 MFX & PRP 22 43.9 50.0   
30.1 Control group (Mosaicplasty) 13 37.6 15.4    > 0.2
Murphy et al. [54] Knee Surg Sports Traumatol Arthrosc Retrospective 36.7 MAST 38 31.2 35.0   1.7
Nguyen et al. [55] Am J Sports Med Retrospective 44.7 OAT & BMA, or PRGF 38 0.0 26.0   2.5
Richter et al. [56] Foot Ankle Surg Prospective 24.0 MAST & BMC 26 28.0 33.0   1.1
Richter et al. [57] Foot Ankle Surg Prospective 24.4 MAST & BMC 129 41.0 35.3   1.6
23.8 AMIC & PBC 129 40.0 35.6   1.8
  1. BMC—bone marrow concentrate, PBC—peripheral blood concentrate, MAST—matrix-associated stem cell transplantation, AMIC—autologous matrix-induced chondrogenesis, PRP—platelet-rich plasma, mACI—membrane-assisted autologous chondrocyte implantation, PRGF—platelet-rich grow factors